Johns Hopkins and AccessHope partner to expand remote access to cancer expertise for employers

Scientists identify genes that help cancer cells survive in the bloodstream

Scientists at the Johns Hopkins Kimmel Cancer Center have identified 16 genes that breast cancer cells use to survive in the bloodstream after they’ve escaped the low-oxygen regions of a tumor. Each is a potential therapeutic target to stop cancer recurrence, and one—MUC1—is already in clinical trials. The research was published online Sept. 28 in...

November 08, 2024

Vol.50 No.42

Clinical Roundup

Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence

People with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to an analysis by Johns Hopkins Kimmel Cancer Center investigators.

September 13, 2024

Vol.50 No.34

Clinical Roundup

Esopredict test helps ID patients at high risk of esophageal cancers

Esopredict, a test developed by Johns Hopkins Kimmel Cancer Center investigators, could give gastroenterologists insight into which patients with Barrett’s esophagus are likely to progress to esophageal cancer or an abnormal collection of cells called high-grade dysplasia, according to a recent study. This information could help physicians determine how to monitor or manage patients during clinical care.

September 06, 2024

Vol.50 No.33

Clinical Roundup

DDR gene mutations associated with complete response to chemo in bladder cancer

Tumors with alterations in any of three specific genes were more likely than other tumors to be eliminated by cisplatin-based chemotherapy.

August 02, 2024

Vol.50 No.31

In Brief

Lei Zheng named executive director of Mays Cancer Center

Lei Zheng was named executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, and vice president for oncology for the University of Texas Health Science Center at San Antonio.

July 12, 2024

Vol.50 No.28

Clinical Roundup

Novel Co-STAR receptor shows promise treating cancers in preclinical study

Using genetic engineering techniques, investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center, the Lustgarten Laboratory and Bloomberg~Kimmel Institute for Cancer Immunotherapy have designed a novel type of cell to recognize and fight cancer.

July 12, 2024

Vol.50 No.28

Johns Hopkins and AccessHope partner to expand remote access to cancer expertise for employers

YOU MAY BE INTERESTED IN

Scientists identify genes that help cancer cells survive in the bloodstream

Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence

Esopredict test helps ID patients at high risk of esophageal cancers

DDR gene mutations associated with complete response to chemo in bladder cancer

Lei Zheng named executive director of Mays Cancer Center

Novel Co-STAR receptor shows promise treating cancers in preclinical study

Renew today!

Subscriber content

Never miss an issue!

Login